Clinical Trial Update: Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Chiauranib in patients with small cell lung cancer and advanced solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• Chiauranib (Chiauranib)

Snippet

Sponsor: Chipscreen Biosciences, Ltd. | Conditions: Small Cell Lung Cancer, Advanced Solid Malignant Tumor | Phase 1, Phase 2 | Status: RECRUITING